University of Cincinnati Tests Cholesterol Drug to Prevent Recurrence of Colorectal Cancer

Physicians at the University of Cincinnati are conducting a seven-year trial to test a cholesterol drug for the prevention of recurring colorectal cancer in patients who have been surgically treated.

Advertisement

The trial, funded by the National Surgical and Adjuvant Bowel and Breast Project, will study whether patients who have had CRC surgically removed can take statins to prevent polyp formation, thereby preventing a recurrence of CRC.

Over five years, the study will compare the effects of the cholesterol-lowering rosuvastatin (Crestor) to a placebo through regular exams and tests. In the last two years, physicians will actively follow -up to monitor CRC recurrence.

Read the release on University of Cincinnati trial.

Read more coverage on colorectal cancer:

Study: 4% Increase in Hospitals Offering Computed Tomographic Colonography

AHRQ Highlights Successful Strategies for Increasing CRC Screening, Infection Prevention

Baylor Health, Eureka Form Alliance for Colorectal Cancer Research

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.